Zacks Research Estimates ResMed’s FY2025 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Stock analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for shares of ResMed in a research note issued on Thursday, February 27th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $9.36 for the year, up from their previous forecast of $9.35. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.40 EPS, Q1 2026 earnings at $2.30 EPS, Q2 2026 earnings at $2.40 EPS, FY2026 earnings at $9.69 EPS, Q1 2027 earnings at $2.50 EPS, Q2 2027 earnings at $2.61 EPS and FY2027 earnings at $10.64 EPS.

RMD has been the subject of several other research reports. Stifel Nicolaus started coverage on ResMed in a report on Friday, December 13th. They issued a “hold” rating and a $250.00 price objective for the company. Piper Sandler raised their price objective on ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a report on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of ResMed in a report on Friday, January 31st. JPMorgan Chase & Co. raised their price objective on ResMed from $270.00 to $286.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Finally, KeyCorp raised their price objective on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $244.73.

ResMed Price Performance

Shares of NYSE RMD opened at $231.31 on Monday. The stock has a market capitalization of $33.97 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 1.53 and a beta of 0.70. The business has a 50-day moving average of $237.07 and a 200-day moving average of $240.02. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed has a fifty-two week low of $172.19 and a fifty-two week high of $263.05.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.

Institutional Investors Weigh In On ResMed

A number of institutional investors have recently made changes to their positions in the company. Menard Financial Group LLC bought a new stake in shares of ResMed during the fourth quarter worth approximately $98,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of ResMed during the fourth quarter worth approximately $19,540,000. ABLE Financial Group LLC boosted its holdings in shares of ResMed by 2.8% during the fourth quarter. ABLE Financial Group LLC now owns 2,639 shares of the medical equipment provider’s stock worth $604,000 after acquiring an additional 72 shares during the period. Forum Financial Management LP acquired a new stake in shares of ResMed in the fourth quarter valued at approximately $273,000. Finally, Toronto Dominion Bank raised its position in shares of ResMed by 4.3% in the fourth quarter. Toronto Dominion Bank now owns 51,349 shares of the medical equipment provider’s stock valued at $11,743,000 after buying an additional 2,099 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now owns 77,218 shares in the company, valued at $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the sale, the chief executive officer now owns 455,472 shares of the company’s stock, valued at approximately $107,842,105.44. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 19,186 shares of company stock worth $4,541,226 over the last quarter. Company insiders own 0.71% of the company’s stock.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Thursday, February 13th. ResMed’s payout ratio is currently 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.